Firm will team up with Quintiles to manage Phase I Clinical Trial Unit.
DynPort Vaccine, a CSC company, received a contract valued at approximately $32.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) to establish and operate a Phase I trial unit for infectious disease therapeutics.
DVC will team up with Quintiles Transnational to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year for the seven-year contract period.
DVC will provide overall project management, clinical operations management, quality assurance, and co-development of protocols. Quintiles will provide Phase I clinical research and support services for the implementation and conduct of approved Phase I trial protocols.
Trials will include therapeutic candidates for a broad range of infectious diseases. Investigational products tested could include measures to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
Quintiles’ portion of the contract will take place in its new 150-bed Phase I clinical research unit in Overland Park, KS. DVC will perform its duties at its headquarters in Frederick, MD.
